Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
Drugs targeting myostatin reverse muscle wasting in animal models, but have limited efficacy in patients. The authors show that the myostatin pathway is downregulated in patients, possibly explaining the poor outcome of anti-myostatin approaches, and that it can be reactivated by correcting disease-...
Guardado en:
Autores principales: | Virginie Mariot, Romain Joubert, Christophe Hourdé, Léonard Féasson, Michael Hanna, Francesco Muntoni, Thierry Maisonobe, Laurent Servais, Caroline Bogni, Rozen Le Panse, Olivier Benvensite, Tanya Stojkovic, Pedro M. Machado, Thomas Voit, Ana Buj-Bello, Julie Dumonceaux |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2403fa3958844630ae86e529ecfe4061 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A highly prevalent SINE mutation in the myostatin (MSTN) gene promoter is associated with low circulating myostatin concentration in Thoroughbred racehorses
por: Victoria O’Hara, et al.
Publicado: (2021) -
Cytotoxic aggregation and amyloid formation by the myostatin precursor protein.
por: Carlene S Starck, et al.
Publicado: (2010) -
Plasma and muscle myostatin in relation to type 2 diabetes.
por: Claus Brandt, et al.
Publicado: (2012) -
JNK regulates muscle remodeling via myostatin/SMAD inhibition
por: Sarah J. Lessard, et al.
Publicado: (2018) -
Proteomic Studies on the Mechanism of Myostatin Regulating Cattle Skeletal Muscle Development
por: Hui Sheng, et al.
Publicado: (2021)